Alcidion Group Limited (ASX:ALC) advises that its Board has today announced the resignation of Ray Blight as Non-Executive Director, effective 30 June 2021.
This announcement coincides with the conclusion of Mr. Blight’s contracting agreement, which commenced on 1 September 2019 following his retirement as Executive Chair of Alcidion. Mr. Blight was due for re-election at the Company’s next AGM in November on rotation.
As part of Alcidion’s Board renewal and succession planning process, in the six months leading up to the Annual General Meeting, the Company evaluates its Board composition, performance, and skills ahead of the nomination of Directors due for re-election. This is a Board-led initiative that supports an active and measured process to ensure the Board reflects the current and future needs of Alcidion as the Company continues its path of accelerated growth.
Alcidion is well advanced in the identification of suitable independent Non-Executive Director candidates to replace Mr. Blight and expects to announce a replacement in the near term.
Ray Blight co-founded Alcidion in 2000 with Dr. Malcolm Pradhan and served as group CEO and Executive Chairman until the acquisitions of MKM Health and Patientrack in July 2019. In January 2019, Ray stepped down from executive duties and assumed the role of Non-Executive Chairman until September 2019.
Rebecca Wilson, Chair of Alcidion said, “On behalf of the Board, I’d like to thank Ray for his contribution to the Company in his multiple capacities; as the founder of Alcidion, as CEO, Executive Chair and NED of the Board. His deep history with Alcidion and knowledge of the health innovation industry has provided significant value over the last two decades.”
“We are well advanced in appointing a replacement Non-Executive Director, with a strong pool of candidates highly engaged and enthused at the prospect of joining the Alcidion Board at this time of significant momentum and strong growth prospects,” said Ms Wilson.
Outgoing Non-Executive Director of Alcidion Ray Blight said, “It has been a privilege to see Alcidion grow over the past two decades, delivering technology that has been at the forefront of healthcare’s transition to digital delivery. The Company is backed by an excellent leadership team, whom I know ensures Alcidion is in the best position to deliver value to the healthcare providers it works with, the patients its technology is used for, and the shareholders invested in the Alcidion journey.”
An Appendix 3Z is attached to this announcement in relation to Ray Blight’s resignation.